Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
NCT01860976 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 489
Last updated 2022-04-05
Summary
The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis
Conditions
Interventions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-17
- Primary Completion
- 2015-07-14
- Completion
- 2020-06-30
Countries
- United States
- Argentina
- Brazil
- Canada
- Chile
- Colombia
- Czechia
- France
- Germany
- Greece
- Israel
- Italy
- Mexico
- Peru
- Poland
- South Africa
- Spain
Study Locations
More Related Trials
-
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
NCT03104374 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
NCT06176508 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
NCT01925768 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
NCT00809614 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
NCT00679731 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
NCT03963401 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
NCT01877668 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
NCT01077362 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
NCT02798211 ·Status: COMPLETED ·Phase: PHASE4
-
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
NCT02719171 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424 ·Status: RECRUITING ·Phase: PHASE3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
NCT03104400 ·Status: COMPLETED ·Phase: PHASE3
-
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00338754 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
NCT01392326 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
NCT02745080 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT03022045 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
NCT01172938 ·Status: COMPLETED ·Phase: PHASE3
-
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT01208090 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00691964 ·Status: COMPLETED ·Phase: PHASE3
-
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
NCT01882439 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Picankibart in Patients With Active Psoriatic Arthritis
NCT07295509 ·Status: RECRUITING ·Phase: PHASE2/PHASE3